Hypertension in an urban HIV-positive population compared with the general population: Influence of combination antiretroviral therapy

Journal of Hypertension

Volumn 26, Issue 11, 2008, Pages 2126-2133

  Baekken, Morten ^a,b   Os, Ingrid ^b,c   Sandvik, Leiv ^a   Oektedalen, Olav ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Department of Nephrology ^*  (Norway)

Author keywords

Blood pressure; BMI; Combination antiretroviral therapy; HIV; Hypertension; Inflammation; Isolated systolic hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ETHNIC DIFFERENCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; URBAN POPULATION; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; HEALTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL; STATISTICS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COMORBIDITY; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; PREVALENCE; URBAN HEALTH;

EID: 56049099540     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830ef5fb     Document Type: Article

References (47)

1. d'ArminioMonforte A, Sabin CA, Phillips A, Sterne J,MayM, Justice A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-423.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130.
5. Smit C, Geskus R,Walker S, Sabin C, Coutinho R, Porter K, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
7. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD AIDS 2001; 12:463-468.
8. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
9. Friis-Moller N,Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
10. Iloeje UH, Yuan Y, L'Italien G, Mauskopf J, Holmberg SD, Moorman AC, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6:37-44.
11. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, Clinical Epidemiology Group from the French Hospital D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV- infected men. AIDS 2003; 17:2479-2486.
12. Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis 2003; 37:959-972.
13. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
14. d'Arminio A, Sabin CA, Phillips AN, Reiss P,Weber R, Kirk O, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18:1811-1817.
15. Hsue PY, Lo JC, Franklin AR, Bolger AF, Martin JN, Deeks SG,Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
16. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22:731-736.
17. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, FiliceG. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21:1377-1382.
18. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7:404-410.
19. Jerico C, Knobel H, Montero M, Sorli ML, Guelar A, Gimeno JL, et al. Hypertension in HIV-infected patients: prevalence and related factors. AmJ Hypertens 2005; 18:1396-1401.
20. Jung O, Bickel M, Ditting T, Rickerts V, Welk T, Helm EB, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant 2004; 19:2250-2258.
21. Palacios R, Santos J, Garcia A, Castells E, Gonzalez M, Ruiz J, Marquez M. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIVMed 2006; 7:10-15.
22. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953-960.
23. Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 1999; 317:232-237.
24. Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS 2001; 15:805-807.
25. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4:411-416.
26. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20:1019-1026.
27. Thiebaut R, El-Sadr WM, Frus-Moller N, Rickenbach M, Reiss P, Monforte ADA, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005; 10:811-823.
28. Holmen J, Midthjell K, Kruger O, Langhammer A, Holmen T, Bratberg G, et al. The Nord-Trøndelag Health Study (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiologi 2003; 13:19-32.
29. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modeling study. BMJ 2005; 331:551.
30. Ormaasen V, Bruun JN, Sandvik L, Holberg-Petersen M, Gaarder PI. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection. Scand J Infect Dis 2003; 35:383-388.
31. Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30:1135-1143.
32. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
33. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000; 2:478-481.
34. Baliga RS, Chaves AA, Jing L, Ayers LW, Bauer JA. AIDS-related vasculopathy: evidence for oxidative and Infiammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005; 289:H1373-H1380.
35. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18:1037-1041.
36. Engstrom G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgarde F. Blood pressure increase and incidence of hypertension in relation to infiammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22:2054-2058.
37. Bergersen BM, Sandvik L, Ellingsen I, Bruun JN. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med 2005; 6:260-267.
38. Sattler FR, Qian D, Louie S, Johnson D, BriggsW, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-2010.
39. de Gaetano Donati K, Rabagliati R, Tumbarello M, Tacconelli E, Amore C, Cauda R, Lacoviello L. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003; 17:765-768.
40. Schillaci G, De Socio GVL, Pirro M, Savarese G, Mannarino MR, Baldelli F, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 2005; 25:2381-2385.
41. Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005; 68:690-700.
42. Baekken M, Os I, Sandvik L, Oektedalen O. Microalbuminuria associated with indicators of Infiammatory activity in an HIV-positive population. Nephrol Dial Transplant 2008 [Epub ahead of print]. doi: 10.1093/ndt/ gfn236.
43. Kestenbaum B, Rudser KD, de Boer IH, Peralta CA, Fried LF, Shlipak MG, et al. Differences in kidney function and incident hypertension: the multiethnic study of atherosclerosis. Ann Intern Med 2008; 148:501-508.
44. Franklin SS. Systolic blood pressure: it's time to take control. Am J Hypertens 2004; 17:49S-54S.
45. DroyvoldWB,Midthjell K, Nilsen TIL, Holmen J. Change in body mass index and its impact on blood pressure: a prospective population study. Int J Obes 2005; 29:650-655.
46. Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences: the Tromso Study, 1986-1995.Arch Intern Med 2000; 160:2847-2853.
47. Antikainen RL, Moltchanov VA, Chukwuma C Sr, Kuulasmaa KA, Marques- Vidal PM, Sans S, et al. Trends in the prevalence, awareness, treatment and control of hypertension: theWHOMONICA Project. Eur JCardiovasc Prev Rehabil 2006; 13:13-29.